Breaking Boundaries: Kura Oncology to Showcase Exciting Research at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
– Presentations to highlight preclinical data supporting combination of KO-2806 with targeted therapies, including TKIs, KRASG12C inhibitors and KRASG12D inhibitors –
SAN DIEGO, Oct. 04, 2023 (GLOBE NEWSWIRE) — Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that three groundbreaking presentations will be showcased at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. The presentations will focus on the preclinical data supporting the combination of KO-2806 with targeted therapies, including TKIs, KRASG12C inhibitors, and KRASG12D inhibitors.
The Impact on Me
As a cancer patient, this exciting research from Kura Oncology represents a potential game-changer in the field of precision medicine for cancer treatment. The combination of KO-2806 with other targeted therapies could significantly improve treatment outcomes and offer new hope for patients like myself. This research has the potential to provide more personalized and effective treatment options, ultimately improving the quality of life and prognosis for cancer patients.
The Impact on the World
The research presented by Kura Oncology at the AACR-NCI-EORTC International Conference has the potential to revolutionize the way cancer is treated globally. By combining KO-2806 with other targeted therapies, this research could lead to more effective and tailored treatment approaches for a wide range of cancer types. This could have a profound impact on the healthcare industry, paving the way for more personalized and precision therapies that improve patient outcomes and overall survival rates.
Conclusion
In conclusion, the research presented by Kura Oncology at the AACR-NCI-EORTC International Conference is groundbreaking and has the potential to significantly advance the field of cancer therapeutics. This innovative approach to combining KO-2806 with targeted therapies could offer new hope for cancer patients and revolutionize the way cancer is treated worldwide. The future of precision medicine in cancer treatment looks promising, thanks to the pioneering work of companies like Kura Oncology.
